{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:53:07Z","timestamp":1776873187953,"version":"3.51.2"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            isolates, 2,614\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            isolates, and 1,193\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 \u03bcg\/ml for penicillin-susceptible, -intermediate, and -resistant\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            strains, respectively; 0.5 and 1 \u03bcg\/ml for \u03b2-lactamase-positive and -negative\n            <jats:italic>H. influenzae<\/jats:italic>\n            strains, respectively; and 0.12 and 0.5 \u03bcg\/ml for \u03b2-lactamase-negative and -positive\n            <jats:italic>M. catarrhalis<\/jats:italic>\n            strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.\n          <\/jats:p>","DOI":"10.1128\/aac.46.2.550-555.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"550-555","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Activities of Faropenem, an Oral \u03b2-Lactam, against Recent U.S. Isolates of\n            <i>Streptococcus pneumoniae<\/i>\n            ,\n            <i>Haemophilus influenzae<\/i>\n            , and\n            <i>Moraxella catarrhalis<\/i>"],"prefix":"10.1128","volume":"46","author":[{"given":"Ian A.","family":"Critchley","sequence":"first","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah C.","family":"Draghi","sequence":"additional","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Jones","sequence":"additional","affiliation":[{"name":"1217 KP Hilversum, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde","family":"Thornsberry","sequence":"additional","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Murfitt","sequence":"additional","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02013089"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332408"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/35.4.535","volume":"35","year":"1995","unstructured":"Cormican, M. G., and R. N. Jones. 1995. Evaluation of the in vitro activity of faropenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria. J. Antimicrob. Chemother.35:535\u2013539.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.292"},{"key":"e_1_3_2_6_2","first-page":"1","volume":"36","year":"1995","unstructured":"Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. Rev.36(Suppl A):1\u201317.","journal-title":"J. Antimicrob. Chemother. Rev."},{"key":"e_1_3_2_7_2","first-page":"5","volume":"11","year":"1999","unstructured":"Felmingham, D., and J. Washington. 1999. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992\u20131996. J. Chemother.11(Suppl. 1):5\u201321.","journal-title":"J. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(99)90037-1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1472"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.1974"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.3.2.171"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.203-207.2001"},{"key":"e_1_3_2_13_2","unstructured":"Manual of clinical microbiology 7th ed. 1999"},{"key":"e_1_3_2_14_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 10th informational supplement vol. 20 2000"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.6.828"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.12.2137"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/46.1.101","volume":"46","year":"2000","unstructured":"Okuda, J., M. Otsuki, T. Oh, and T. Nishino. 2000. In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J. Antimicrob. Chemother.46:101\u2013108.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1591"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2599"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2902"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.6.749"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.550-555.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.550-555.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:36:17Z","timestamp":1645464977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.2.550-555.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1128\/AAC.46.2.550-555.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.2.550-555.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"2001-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}